AIDS drug ready to go on market
The AZT based therapy for AIDS will be made available within weeks to thousands. Officials said the drug extends life and lowers infection rates in some patients but is not a cure and has serious side effects. The trial was halted early to allow placebo participants access and showed fewer deaths among AZT recipients.
MENTIONED IN THIS ARTICLE
Washington
Department of Health and Human Services
Burroughs Wellcome Co
Research Triangle Park, N.C
Robert E. Windom
Health and Human Services
Food and Drug Administration
Drugs showing promise in AIDS research list
New York AP reports Azidothymidine may extend lives of some AIDS patients and is among drugs studied by the National Cancer Institute. Suramin is unlikely as a sole AIDS treatment but could aid in combinations. Ribavirin may affect the virus but impact remains unclear. Foscarnet risks kidney failure. Dideoxycytidine to begin first human trials with 24 volunteers this fall.
MENTIONED IN THIS ARTICLE
New York
National Cancer Institute
Suramin
France
Rock Hudson
Also Mentioned on This Page
Windom
BIG Tex Furniture
TWIP
VISA
Mastercard
Brass & Glass
Odessa, Texas